Tolerability, safety, and pharmacokinetics (PK) of URC102 will be assessed after 7-day repeated oral dose in healthy adult Korean males. In addition, pharmacodynamic (PD) response of blood and urinary uric acid levels will be assessed.
The purpose of this study is to assess the safety, tolerability, PK and PD of URC102 in healthy subjects.